Clinical Trial

Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

Study acronym: TIMPANI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-10-18; most recent amendment 2025-12-08.
Status change: Not Yet Recruiting → Recruiting 2023-09-21
Trial Details
NCT Number NCT05590455
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions Tuberculous Meningitis, HIV I Infection
Enrollment 130 participants
Start Date 2023-04-11
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-15